CL2021003243A1 - Tratamientos de angioedema - Google Patents

Tratamientos de angioedema

Info

Publication number
CL2021003243A1
CL2021003243A1 CL2021003243A CL2021003243A CL2021003243A1 CL 2021003243 A1 CL2021003243 A1 CL 2021003243A1 CL 2021003243 A CL2021003243 A CL 2021003243A CL 2021003243 A CL2021003243 A CL 2021003243A CL 2021003243 A1 CL2021003243 A1 CL 2021003243A1
Authority
CL
Chile
Prior art keywords
treatments
angioedema
aenh
demand
bradykinin
Prior art date
Application number
CL2021003243A
Other languages
English (en)
Inventor
Edward Paul Feener
Sally Louise Marsh
Andreas Maetzel
Michael David Smith
Christopher Martyn Yea
Original Assignee
Kalvista Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalvista Pharmaceuticals Ltd filed Critical Kalvista Pharmaceuticals Ltd
Publication of CL2021003243A1 publication Critical patent/CL2021003243A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a tratamientos de angioedema y específicamente angioedema no hereditario mediado por bradiquinina (BK-AEnH). En particular, la presente invención proporciona tratamientos a solicitud de angioedema no hereditario mediado por bradiquinina (BKAEnH) mediante la administración oral de un inhibidor de calicreína del plasma a un paciente que lo necesita a solicitud. Se proporciona también tratamientos regulares (o continuos) de BK-AEnH.
CL2021003243A 2019-06-14 2021-12-06 Tratamientos de angioedema CL2021003243A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962861758P 2019-06-14 2019-06-14
GBGB1910125.2A GB201910125D0 (en) 2019-07-15 2019-07-15 Treatments of angioedema

Publications (1)

Publication Number Publication Date
CL2021003243A1 true CL2021003243A1 (es) 2022-09-30

Family

ID=67700187

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2021003243A CL2021003243A1 (es) 2019-06-14 2021-12-06 Tratamientos de angioedema
CL2023000699A CL2023000699A1 (es) 2019-06-14 2023-03-10 Tratamientos de angioedema

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2023000699A CL2023000699A1 (es) 2019-06-14 2023-03-10 Tratamientos de angioedema

Country Status (17)

Country Link
US (1) US20220226293A1 (es)
EP (1) EP3982961A1 (es)
JP (1) JP2022537913A (es)
KR (1) KR20220024221A (es)
CN (2) CN118078821A (es)
AR (1) AR119159A1 (es)
AU (1) AU2020293616A1 (es)
BR (1) BR112021024447A2 (es)
CA (1) CA3142220A1 (es)
CL (2) CL2021003243A1 (es)
GB (1) GB201910125D0 (es)
IL (1) IL288612A (es)
MA (1) MA56188A (es)
MX (1) MX2021014558A (es)
SG (1) SG11202113375PA (es)
TW (1) TW202112371A (es)
WO (1) WO2020249979A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
WO2023209381A1 (en) 2022-04-27 2023-11-02 Kalvista Pharmaceuticals Limited Formulations of a plasma kallikrein inhibitor
CN116003386B (zh) * 2022-11-20 2024-03-26 药康众拓(北京)医药科技有限公司 一种氘代n-苄基吡啶酮吡唑甲酰胺类化合物、药物组合物和用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
GB9019558D0 (en) 1990-09-07 1990-10-24 Szelke Michael Enzyme inhibitors
SE9301911D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptide derivatives
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
GB0205527D0 (en) 2002-03-08 2002-04-24 Ferring Bv Inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
CA2658523C (en) 2006-07-31 2012-06-12 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
JP2013121919A (ja) 2010-03-25 2013-06-20 Astellas Pharma Inc 血漿カリクレイン阻害剤
WO2012004678A2 (en) 2010-07-07 2012-01-12 The Medicines Company (Leipzig) Gmbh Serine protease inhibitors
EP2595986A2 (en) 2010-07-14 2013-05-29 Addex Pharma SA Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
GB2494851A (en) 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
RU2712621C2 (ru) 2013-05-23 2020-01-30 Калвиста Фармасьютикалз Лимитед Азотсодержащие гетероциклические производные, полезные в качестве ингибитора калликреина плазмы
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201721515D0 (en) * 2017-12-21 2018-02-07 Kalvista Pharmaceuticals Ltd Dosage forms comprising a plasma kallikrein inhibtor

Also Published As

Publication number Publication date
CA3142220A1 (en) 2020-12-17
TW202112371A (zh) 2021-04-01
AU2020293616A1 (en) 2022-01-27
CL2023000699A1 (es) 2023-10-30
MX2021014558A (es) 2022-04-06
BR112021024447A2 (pt) 2022-01-18
MA56188A (fr) 2022-04-20
SG11202113375PA (en) 2021-12-30
US20220226293A1 (en) 2022-07-21
IL288612A (en) 2022-02-01
JP2022537913A (ja) 2022-08-31
KR20220024221A (ko) 2022-03-03
WO2020249979A1 (en) 2020-12-17
AR119159A1 (es) 2021-12-01
GB201910125D0 (en) 2019-08-28
CN113993520A (zh) 2022-01-28
EP3982961A1 (en) 2022-04-20
CN118078821A (zh) 2024-05-28

Similar Documents

Publication Publication Date Title
CL2021003243A1 (es) Tratamientos de angioedema
CL2023000639A1 (es) Tratamientos de angioedema hereditario
PH12017502103A1 (en) Methods and kits for treating depression
CL2018002826A1 (es) Proteínas f de prefusión del virus respiratorio sincicial (vrs) solubles y estabilizadas
CL2019000844A1 (es) Compuesto de piridina.
WO2018234568A3 (en) HYDROXYNORKETAMINE FOR USE IN TREATING DEPRESSION
BR112017018522A2 (pt) composições e métodos para diagnóstico e tratamento do câncer
BR112019003577A2 (pt) métodos de tratamento da semente e produtos resultantes
MX2017011655A (es) Compuestos de aza-piridona y usos de estos.
BR112018011622A2 (pt) método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae
MX2018005233A (es) Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer.
EP4137147A3 (en) Uses of abaloparatide in reducing fracture risk
MX2017001490A (es) Combinaciones de farmacos para tratar mieloma multiple.
PH12018501943A1 (en) Pharmaceutical compositions for the treatment of cancer
CO2017009182A2 (es) Cepas bacterianas productoras de histamina para tratamiento del cáncer
PH12020551331A1 (en) Treatment and prevention of pre-eclampsia
WO2020109233A3 (en) Trmt2a inhibitors for use in the treatment of polyglutamine diseases
MX2021002818A (es) Métodos para tratar el cáncer mediante la inhibición de la enzima conjugadora de ubiquitina e2 k (ube2k).
MX2017002093A (es) Terapia con anticuerpos para vih como sustituto de tratamiento.
MD3638370T2 (ro) Tratamentul migrenei cu acetil-leucină
MX2020012065A (es) Compuestos de ciclopentano.
UY35165A (es) Método profiláctico o terapéutico para el síndrome de sjogren
MX2021008887A (es) Minociclina para el tratamiento del sindrome de pitt-hopkins.
TN2017000517A1 (en) MULTl-PEPTIDE COMPOSITION
ZA202201221B (en) Cyclopentane compounds